Edition:
United States

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

7.37USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85,286
52-wk High
$9.22
52-wk Low
$3.76

Latest Key Developments (Source: Significant Developments)

Adaptimmune Therapeutics Q3 loss per share $0.00
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​.  Full Article

Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics
Monday, 11 Sep 2017 08:31am EDT 

Sept 11 (Reuters) - Matrix Capital Management Co Lp::Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing.  Full Article

GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
Thursday, 7 Sep 2017 07:30am EDT 

Sept 7 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​.Adaptimmune Therapeutics Plc - ‍Adaptimmune will receive up to £48 million ($61 million) from GSK over course of transition period​.Adaptimmune Therapeutics Plc - ‍anticipate transition of NY-ESO to GSK to be completed over coming months​.  Full Article

Adaptimmune reports Q2 revenue $3.5 million
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Adaptimmune Therapeutics Plc ::Adaptimmune reports second quarter 2017 financial results.Q2 revenue $3.5 million.Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S.Q2 loss per share $0.04.Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.  Full Article

Biolife Solutions executes supply agreement with Adaptimmune for Cryostor
Wednesday, 14 Jun 2017 06:00am EDT 

June 14 (Reuters) - Biolife Solutions Inc :Biolife solutions executes supply agreement with adaptimmune for cryostor® use in spear t-cell platform.Biolife solutions inc - that it has entered into a supply agreement with nasdaq-listed adaptimmune therapeutics plc.  Full Article

Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
Monday, 5 Jun 2017 09:50am EDT 

June 5 (Reuters) - Adaptimmune Therapeutics PLC ::Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting.From ongoing NY-ESO Synovial Sarcoma study, NY-ESO continues to be generally well-tolerated.From ongoing NY-ESO Synovial Sarcoma study, initial anti-tumor activity observed in all ongoing cohorts.  Full Article

Adaptimmune Q1 loss per share $0.05
Wednesday, 10 May 2017 07:30am EDT 

May 10 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports first quarter 2017 financial results.Q1 revenue $2.9 million.Q1 revenue view $4.9 million -- Thomson Reuters I/B/E/S.Adaptimmune therapeutics plc - offerings in march and april raised net proceeds of $103.2 million; operations funded through to late 2019.Q1 loss per share $0.05.  Full Article

Adaptimmune Therapeutics proposes public offering of American Depositary Shares
Tuesday, 21 Mar 2017 04:55pm EDT 

Adaptimmune Therapeutics Plc : Adaptimmune Therapeutics Plc proposes public offering of American Depositary Shares .Adaptimmune Therapeutics Plc - net proceeds from offering to be used to advance co's pipeline of Spear T-cell candidates through clinical trials.  Full Article

Adaptimmune Therapeutics reports Q4 revenue $8.5 mln vs $4 mln
Monday, 13 Mar 2017 07:30am EDT 

Adaptimmune Therapeutics Plc : Adaptimmune reports fourth quarter and full year 2016 financial results . Q4 revenue $8.5 million versus $4.0 million .Q4 revenue view $3.8 million -- Thomson Reuters I/B/E/S.  Full Article

Adaptimmune Therapeutics reports Q4 loss per share $0.04
Monday, 13 Mar 2017 07:30am EDT 

Adaptimmune Therapeutics Plc : Adaptimmune reports fourth quarter and full year 2016 financial results . Q4 revenue $8.5 million versus $4.0 million . Q4 revenue view $3.8 million -- Thomson Reuters I/B/E/S . Adaptimmune Therapeutics Plc - revenue for three months ended December 31, 2016 was $8.5 million compared to $4.0 million in same quarter of prior year . Adaptimmune Therapeutics Plc - as of december 31, 2016, adaptimmune had a total liquidity position of $181.5 million . Adaptimmune Therapeutics Plc qtrly loss per share $0.04 .Adaptimmune Therapeutics Plc - company believes that this balance will fund operations through mid-year 2018.  Full Article

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates